afr, page-10

"Several pharmaceutical companies, including AstraZeneca, GSK, Novartis, Pfizer and Bristol-Myers Squibb are developing multi-kinase inhibitors for use in cancer treatment. However, none of them are currently being tested against melanoma."

This is a good point. We can only hope that PI-88 works where others have failed. If it works I can see an sp of $2.50-$2.80 being sustained but if it doesn't we're headed for $1.

Thank you for bringing this to our attention.